|
- This substantial amendment comprises changes to the protocol. Primarily to include patients into the TICH-3 trial that have had an Intracranial haemorrhage (ICH) while on Direct Oral Anticoagulant (DOAC). This was supported by the findings from the TICH- NOAC trial undertaken by Prof Lyrer et al in Switzerland. Enabling this protocol amendment will allow prompt recruitment of patients to the trial that are on DOACs experiencing ICH.
- Other formatting changes and small clarifications have been made, full details can be viewed within the locked amendment tool document.
|